Cresco Labs Q4 revenue slightly beats estimates on margin boost

Overview

• Cannabis products firm reported preliminary Q4 revenue of $162 mln, slightly beating analyst expectations

• Company achieved adjusted EBITDA of $40 mln for Q4

• Adjusted gross margin for Q4 improved to 52.2%

Outlook

• Cresco Labs aims to capitalize on industry consolidation and federal reform

• Company focuses on organic expansion and selective acquisitions

• Cresco Labs highlights strength in brand share and retail execution

Result Drivers

• MARGIN IMPROVEMENT - Cresco Labs reported sequential improvement in profitability metrics, including a gross profit of $83 million and an adjusted gross margin of 52.2%

• STRATEGIC POSITIONING - Management highlighted a focused strategy on enhancing competitive positioning and expanding margins

• INDUSTRY CONSOLIDATION - Company noted the impact of industry consolidation and its strategic positioning to capitalize on these changes

Company press release: ID:nBwMTCtwa

Key Details

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Cresco Labs Inc is C$2.25, about 69.2% above its March 4 closing price of C$1.33

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.